UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 12, 2014
Supernus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
Incorporation)
|
0-50440 |
|
20-2590184 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
1550 East Gude Drive, Rockville MD |
|
20850 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (301) 838-2500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors and Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 12, 2014, the Compensation Committee of the Board of Directors of Supernus Pharmaceuticals, Inc. approved an amendment revising Section 3(b) of the form of Executive Retention Agreement (the “Agreement”) filed on August 11, 2014 as Exhibit 10.1 to Form 8-K. The amended form of Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit
The following document is filed as an Exhibit pursuant to Item 5.02 hereof:
Exhibit 10.1 — Form of Executive Retention Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
SUPERNUS PHARMACEUTICALS, INC. | |
|
|
| |
|
DATED: September 18, 2014 |
By: |
/s/ Gregory S. Patrick |
|
|
Gregory S. Patrick | |
|
|
Vice-President and Chief Financial Officer | |